Global Molecular Diagnostics Market-Focus on Infectious Diseases (HPV/Chlamydia/Gonorrhea) & Genetic Testing (HLA) - Industry Outlook 2022

Abstract
Molecular diagnostics is used for detecting patient’s susceptibility to a disease by tests for detecting and characterizing pathogenic mutations in DNA and RNA samples. It is the most dynamic segment of the global in vitro diagnostics market, given the advantages of precise genetic information over traditional tests. Molecular diagnostics in healthcare has been disseminating around the world at a robust growth rate due its unique ability to unlock molecular information of patients. The market has burgeoned in span of 25 years. It is further poised to reach new heights by breaching US$ 11 billion mark by 2022 by growing at a CAGR of 9.2% in the forecasted period 2016-22.

In terms of market structure, molecular diagnostics industry is classified into three broad categories - clinical infectious disease, genomics and blood donor screening. The clinical infectious disease segment has two sub-segments: virology and bacteriology tests. The genomics segment is further sub-divided into genetic diseases and disorders, cancer testing, HLA testing, and pharmacogenetic testing. Infectious diseases are the largest segment of molecular diagnostics market.

Growth of the industry is fuelled by prevalence of reproductive infectious diseases such as Chlamydia and Gonorrhea, surge in various types of oncology diagnostics, ageing population and government’s mandate on regular screening of HPV and CT/NG. However, complex regulatory framework and lack of clarity on reimbursement are the major factors restraining the growth of the molecular diagnostics market. Key trends prevailing in the industry includes rise in number of strategic industry alliances and use of Next Generation Sequencing (NGS) in clinical molecular diagnostics.

The report provides information on the current scenario, detailed market outlook of the molecular analysis market segments such as Infectious diseases with focus on Human Papilloma virus (HPV) in virology segment and Chlamydia and Gonorrhoea in bacteriology segment. It further analyzes genomics testing market with focus on Human Leukocyte Antigen (HLA) testing. Lastly, Blood Donor Screening market is analysed in the report. Future forecasts on all prominent application areas of the industry till 2022 is also provided in the report. Furthermore, key industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.

Major industry players operating in the market include Roche Holding AG, Novartis AG, Hologic Inc, Abbott Diagnostics, Becton Dickinson and Qiagen NV, among others. Roche Holdings, Novartis AG, Hologic Inc and Qiagen NV are profiled herein based on attributes such as business overview, product segments, financial and business strategies. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global molecular diagnostics market.

Content
1. Executive Summary
2. Research Methodology
3. Introduction
3.1.1 History of Molecular Diagnostics
3.1.2 Molecular Diagnostics vs. Conventional diagnostics
3.1.3 Types of Molecular Diagnostics
4. Molecular Diagnostic Market
4.1 Global Molecular Diagnostics Market Analysis
4.1.1 Market Size by Value (Actual & Forecasted)
4.2.1 Market Share by Segment
4.2.2 Market Share by Discpline
4.2.3 Market Share by Competitors
4.2.4 Market Share by Region
5. Global Molecualr Diagnostics Market Segmentation
5.1 Clinical Infectious Disease Segment
5.1.1 Virology Segment - Human Papilloma virus (HPV) Testing Market
5.1.1.1 Market Size by Value (Actual & Forecasted)
5.1.1.2 Market Size by Volume (Actual & Forecasted)
5.1.1.3 Market Share by Region (Actual & Forecasted)
5.1.1.4 Market Share by Competitors
5.2 Bacteriology - CT/NG Testing Market
5.2.1 Market Size by Value (Actual & Forecasted)
5.2.2 Market Size by Volume (Actual & Forecasted)
5.2.3 Market Share by Region (Actual & Forecasted)
5.2.4 Market Share by Competitors
5.3 Genomics Testing Market – HLA Testing Market
5.3.1 Market Size by Value (Actual & Forecasted)
5.3.2 Human Leukocyte Antigen (HLA) Testing Market
5.4 Blood Donor Screening Segment
6. Global Molecular Diagnostics Market Dynamics
6.1 Market Trends & Developments
6.1.1 Strategic Alliances
6.1.2 Next Generation Sequencing in Clinical Molecular Diagnostics
6.2 Growth Drivers
6.2.1 Surge in Oncology Diagnostics
6.2.2 Prevalence of Reproductive Infectious Disease
6.2.3 Growing geriatric population
6.2.4 Government’s mandate on regular screening of HPV and CT/NG
6.3 Challenges
6.3.1 Complex Regulatory Framework
6.3.2 Lack of Clarity on Reimbursement
7. Competitive Landscape
8. Company Profiles
8.1 Roche Holding AG
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategies
8.2 Novartis AG
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategies
8.3 Qiagen NV
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategies
8.4 Hologic Inc
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategies